公开(公告)号：US09877981B2

公开(公告)日：2018-01-30

申请号：US14434573

申请日：2013-10-09

Applicant: President and Fellows of Harvard College ,  NewSouth Innovations Pty Limited

Inventor： David A. Sinclair ,  Ana P. Gomes ,  Lindsay Wu

IPC: A01N43/04 ,  A61K31/70 ,  A61K31/7064 ,  A61K38/45 ,  A61K48/00 ,  A61K31/706

CPC classification number: A61K31/7064 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/035 ,  A61K31/706 ,  A61K38/45 ,  A61K48/005 ,  C12Y204/02012 ,  C12Y207/07001

Abstract: Disclosed herein are novel compositions and methods for the treatment of age-related diseases, mitochondrial diseases, the improvement of stress resistance, the improvement of resistance to hypoxia and the extension of life span. Also described herein are methods for the identification of agents useful in the foregoing methods.Methods and compositions are provided for the treatment of diseases or disorders associated with mitochondrial dysfunction.The invention relates to methods for treatment and prevention of cancer by administering agents that increase levels of NAD+, such as NAD+ precursors or agents involved in NAD+ biosynthesis.

公开(公告)号：US20160202262A1

公开(公告)日：2016-07-14

申请号：US15066118

申请日：2016-03-10

Applicant: Korea University Research and Business Foundation

Inventor： Man Bock Gu ,  Jee Woong Park ,  Tatavarty Rameshwar

IPC: G01N33/574 ,  G01N33/53 ,  B01D15/38 ,  C12N9/10

CPC classification number: G01N33/57488 ,  B01D15/3823 ,  C12N7/00 ,  C12N9/1048 ,  C12N15/1048 ,  C12N15/115 ,  C12N2310/16 ,  C12N2310/351 ,  C12N2320/13 ,  C12N2330/30 ,  C12N2770/24351 ,  C12Q1/6811 ,  C12Y204/02012 ,  G01N33/5308 ,  G01N33/56983 ,  G01N33/57407 ,  G01N33/6893 ,  G01N2333/183 ,  G01N2333/91142 ,  C12Q2525/205 ,  C12Q2541/101

Abstract: Provided is aptamers screening method based on graphene without target immobilization and the aptamers obtained from the method, and more particularly, a new GO-SELEX method without target immobilization in which a single-stranded nucleic acid pool may react with a non-bound target material or a counter-target material, after which a single-stranded nucleic acid which has not been bound to the target or counter-target may be separated by using the graphene. Also, the specific aptamer obtained through the above-described method may be used for diagnosing target related diseases.

Abstract translation: 提供了基于没有靶固定的石墨烯的适体筛选方法和从该方法获得的适体，更具体地说，没有目标固定的新的GO-SELEX方法，其中单链核酸库可以与未结合的靶材料反应 或反靶物质，之后可以通过使用石墨烯分离未结合靶或对靶的单链核酸。 此外，通过上述方法获得的特异性适体可用于诊断目标相关疾病。

公开(公告)号：US20120328526A1

公开(公告)日：2012-12-27

申请号：US13533686

申请日：2012-06-26

Applicant: Tibor Kristian

Inventor： Tibor Kristian

IPC: A61K31/455 ,  A61K38/45 ,  A61P25/00 ,  A61K49/00 ,  A61K39/395 ,  A61K31/7088 ,  A61K38/00 ,  A61P25/02 ,  A61K31/706 ,  A61P25/28

CPC classification number: A61K31/455 ,  A61K31/706 ,  A61K31/7088 ,  A61K38/45 ,  C12Y204/02012

Abstract: The present invention provides a method of treating a mammal having a neuropathophysiological condition, comprising the step of administering to the mammal in need of such treatment a compound selected from nicotinamide or salts or prodrugs thereof, nicotinamide mononucleotide or salts or prodrugs thereof, nicotinamide adenine dinucleotide or salts or prodrugs thereof, nicotinamide riboside nicotinamide or salts or prodrugs thereof, phosphoribosyltransferase, or combinations thereof. Further provided is a method for treating a mammal having a neuropathophysiological condition or suspected to develop said neuropathophysiological condition, comprising the step of administering to said mammal an inhibitor of CD38 NAD+ glycohydrolase activity.

Abstract translation: 本发明提供治疗具有神经生理生理状况的哺乳动物的方法，其包括向需要这种治疗的哺乳动物施用选自烟酰胺或其盐或前药，烟酰胺单核苷酸或其盐或前药的化合物，烟酰胺腺嘌呤二核苷酸 或其盐或前药，烟酰胺核糖苷烟酰胺或其盐或前药，磷酸核糖转移酶或其组合。 还提供了一种用于治疗具有神经生理学病症或怀疑发展所述神经生理生理状况的哺乳动物的方法，包括向所述哺乳动物施用CD38 NAD +糖酵解酶活性抑制剂的步骤。

公开(公告)号：US20240299505A1

公开(公告)日：2024-09-12

申请号：US18523363

申请日：2023-11-29

Applicant: Industry-University Cooperation Foundation Hanyang University ERICA Campus

Inventor： Chul Su YANG ,  Hyo Keun KIM

IPC: A61K38/45 ,  A61P1/00 ,  C12N9/10

CPC classification number: A61K38/45 ,  A61P1/00 ,  C12N9/1077 ,  C12Y204/02012

Abstract: Provided is a composition for improving, preventing, or treating inflammatory bowel disease including a NAMPT-derived peptide as an active ingredient. The NAMPT-derived peptide of the present disclosure may bind to TRL4 and/or CYBB competitively with extracellular NAMPT (eNAMPT) to inhibit NLRP3 inflammasome activation by the interaction of eNAMPT with TRL4 and/or CYBB, and the NAMPT-derived peptide of the present disclosure further includes a peptide targeting colon tissue to act directly on the colon, so that it is expected to be useful for the prevention or treatment of inflammatory bowel disease.

公开(公告)号：US20180163243A1

公开(公告)日：2018-06-14

申请号：US15837818

申请日：2017-12-11

Applicant: Lindsay Wu ,  David A. Sinclair ,  Kyle Meetze

Inventor： Lindsay Wu ,  David A. Sinclair ,  Kyle Meetze

IPC: C12P19/30 ,  C12N9/12 ,  C12P19/02 ,  C12N11/18

CPC classification number: C12P19/30 ,  C07H19/048 ,  C12N9/1077 ,  C12N9/12 ,  C12N9/1235 ,  C12N11/08 ,  C12N11/10 ,  C12N11/18 ,  C12P19/02 ,  C12P19/36 ,  C12Y204/02011 ,  C12Y204/02012 ,  C12Y207/06001

Abstract: Enzyme-based systems and methods for synthesizing the NAD precursors NMN and NaMN are disclosed. Such methods and systems utilize a mutated form of phosphoribosylpyrophosphate synthetase (PRS) that is superactive and/or other enzyme or enzyme combinations that are immobilized onto a solid surface. The methods and systems substantially increase the efficiency and yield of NAD precursor synthesis.

公开(公告)号：US20170121746A1

公开(公告)日：2017-05-04

申请号：US15296083

申请日：2016-10-18

Applicant: The Procter & Gamble Company

Inventor： Juan Esteban Velasquez ,  Phillip Richard Green ,  John August Wos

IPC: C12P19/28

CPC classification number: C12P19/28 ,  C12Y204/02012 ,  C12Y301/03005

Abstract: A method of making nicotinamide riboside, nicotinamide riboside derivatives, or mixtures thereof is disclosed. The method involves contacting at least the following materials to form a solution: i) α-D-ribose-1-phosphate, α-D-ribose-1-phosphate derivatives, or mixtures thereof; ii) nicotinamide, nicotinamide derivatives, or mixtures thereof; iii) one or more pentosyl transferases (E.C. 2.4.2); iv) and one or more solvents. The resulting solution comprises nicotinamide riboside, nicotinamide riboside derivatives, or mixtures thereof and one or more inorganic orthophosphate anions. The inorganic orthophosphate anions are removed from the solution, leaving a solution of nicotinamide riboside, nicotinamide riboside derivatives, or mixtures thereof.

公开(公告)号：US20150265642A1

公开(公告)日：2015-09-24

申请号：US14434614

申请日：2013-10-09

Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE

Inventor： David A. Sinclair ,  Ana P. Gomes

IPC: A61K31/706 ,  A61K38/45

CPC classification number: A61K31/706 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2217/203 ,  A01K2227/105 ,  A01K2267/0368 ,  A61K38/45 ,  C12Y204/02012 ,  C12Y207/07001 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/423

Abstract: Disclosed herein are novel compositions and methods for the treatment of age-related diseases, mitochondrial diseases, the improvement of stress resistance, the improvement of resistance to hypoxia and the extension of life span. Also described herein are methods for the identification of agents useful in the foregoing methods.Methods and compositions are provided for the treatment of diseases or disorders associated with mitochondrial dysfunction.The invention relates to methods for treatment and prevention of disorders associated with inflammation by administering agents that increase levels of NAD+, such as NAD+ precursors or agents involved in NAD+ biosynthesis.

Abstract translation: 本文公开了用于治疗年龄相关疾病，线粒体疾病，改善耐压性，改善耐氧性和延长寿命的新型组合物和方法。 本文还描述了用于鉴定在前述方法中有用的试剂的方法。 提供了用于治疗与线粒体功能障碍相关的疾病或病症的方法和组合物。 本发明涉及通过施用增加NAD +水平的试剂（例如NAD +前体或参与NAD +生物合成的试剂）来治疗和预防与炎症相关的疾病的方法。

公开(公告)号：US20240085422A1

公开(公告)日：2024-03-14

申请号：US18453286

申请日：2023-08-21

Applicant: Arizona Board of Regents on Behalf of the University of Arizona

Inventor： Joe G.N. Garcia

IPC: G01N33/573 ,  C07K16/40 ,  G01N33/50 ,  G01N33/534

CPC classification number: G01N33/573 ,  C07K16/40 ,  G01N33/5044 ,  G01N33/534 ,  C12Y204/02012 ,  G01N2458/00 ,  G01N2800/40

Abstract: The present disclosure is directed to methods (e.g., in vitro methods) for use of nicotinamide phosphoribosyltransferase (NAMPT) as a biomarker in radiation-induced lung injury (RILI). Provided herein is an in vitro method for the diagnosis, prognosis, and/or monitoring of RILI in a human subject by providing a tissue or plasma sample from the subject and detecting the level of NAMPT therein, wherein a higher level of NAMPT in the tissue or plasma sample from the subject compared to a healthy control or a reference value is indicative for the presence of RILI in the subject. Further provided herein is a method of detecting NAMPT in a human subject by obtaining a biological sample from the subject, detecting the presence of NAMPT in the sample by contacting the sample with a capture agent that specifically binds NAMPT, and detecting binding between NAMPT and the capture agent.

公开(公告)号：US20240043894A1

公开(公告)日：2024-02-08

申请号：US18052595

申请日：2022-11-04

Applicant: Conagen Inc.

Inventor： David Nunn ,  Jacob Edward Vick ,  Bryan Salas-Santiago

IPC: C12P19/36 ,  C12P19/30 ,  C12N9/12 ,  C12N9/10 ,  C12N9/24 ,  C12N9/02 ,  C12N9/14 ,  C12N9/78

CPC classification number: C12P19/36 ,  C12P19/30 ,  C12N9/1235 ,  C12Y207/06001 ,  C12N9/1077 ,  C12Y204/02012 ,  C12N9/1241 ,  C12Y207/07018 ,  C12N9/2497 ,  C12Y302/02001 ,  C12N9/0036 ,  C12Y106/01001 ,  C12N9/14 ,  C12Y306/01022 ,  C12N9/78 ,  C12Y305/01019

Abstract: The present invention relates to microbial production of nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), and nicotinamide adenine dinucleotide (NAD) using a genetically modified bacterium.

公开(公告)号：US20230332114A1

公开(公告)日：2023-10-19

申请号：US18160813

申请日：2023-01-27

Applicant: Mitsubishi Chemical Corporation

Inventor： Takahiro Hayashi ,  Takanori Akiyama

IPC: C12N9/10 ,  C12P19/30

CPC classification number: C12N9/1077 ,  C12P19/30 ,  C12Y204/02012

Abstract: The present invention relates to a modified (mutant) nicotinamide phosphoribosyltransferase, and a method for producing nicotinamide mononucleotide using the same. The modified nicotinamide phosphoribosyltransferase (Nampt) of the present invention comprises the amino acid sequence represented by the following SEQ ID NO: 1 and/or the amino acid sequence represented by the following SEQ ID NO: 2, and has improved activity as compared with wild-type Nampt: (a) SEQ ID NO: 1: S- [V/I] -P-A-X1-X2-H-S-[T/V/I] - [M/V/I] -X3, and (b) SEQ ID NO: 2: X4-[S/I] -D-X5 wherein X1 to X5 are as defined herein.